Based on the NanoSPECT/CT imaging and semiquantitative data, 111In-PSMA-NARI-56 demonstrates excellent tumor specificity and prolonged retention in PSMA-positive LNCaP tumors, with significant radioactivity accumulation sustained up to 96 h post-injection and high initial uptake values of around 4.7–4.8% ID/g within the first 4 h, indicating strong target affinity and favorable imaging characteristics. Here, FOLH1 is linked to neoplasm.